These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10928143)

  • 1. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
    Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
    Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
    J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
    Ozdemir E; Kakehi Y; Okuno H; Yoshida O
    J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
    Davies B; Waxman J; Wasan H; Abel P; Williams G; Krausz T; Neal D; Thomas D; Hanby A; Balkwill F
    Cancer Res; 1993 Nov; 53(22):5365-9. PubMed ID: 8221672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
    Vasala K; Pääkko P; Turpeenniemi-Hujanen T
    Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
    Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
    Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma.
    de Vicente JC; Fresno MF; Villalain L; Vega JA; Hernández Vallejo G
    Oral Oncol; 2005 Mar; 41(3):283-93. PubMed ID: 15743691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
    Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T
    Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
    Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
    Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I; Kopczyński Z
    Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
    Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
    Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters.
    Rodríguez Faba O; Fernández Gómez JM; Palou Redorta J; Escaf Barmadah S; Vizoso F; Villavicencio Mavrich H
    Urol Int; 2007; 78(2):140-4. PubMed ID: 17293654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
    Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
    Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.